BACKGROUND: The demonstration that immune-mediated elimination of leukemia contributes to the success of allogeneic hematopoietic stem cell transplantation (HSCT) has renewed interest in the development of immune-based therapies that might be used to augment the antileukemic effect of HSCT or in patients who are not receiving HSCT. METHODS: The authors reviewed studies that have analyzed the mechanisms that may be operative in T-cell recognition of leukemia after allogeneic HSCT, identified candidate target antigens for immunotherapy of leukemia in transplant and nontransplant patients, and evaluated expression of candidate antigens on leukemic progenitors. RESULTS: A large number of potential targets for T-cell therapy or vaccination have now been identified in human leukemia. Studies to evaluate novel immune-based therapies are now being initiated. CONCLUSIONS: The rapid pace of progress in cellular and molecular immunology has identified new opportunities for developing T-cell therapy or vaccination for leukemia. Obstacles must be addressed before these approaches can be applied broadly, but the promising results of preclinical studies suggest continued efforts in this area will result in the establishment of immunotherapy as a useful modality in clinical practice.
BACKGROUND: The demonstration that immune-mediated elimination of leukemia contributes to the success of allogeneic hematopoietic stem cell transplantation (HSCT) has renewed interest in the development of immune-based therapies that might be used to augment the antileukemic effect of HSCT or in patients who are not receiving HSCT. METHODS: The authors reviewed studies that have analyzed the mechanisms that may be operative in T-cell recognition of leukemia after allogeneic HSCT, identified candidate target antigens for immunotherapy of leukemia in transplant and nontransplant patients, and evaluated expression of candidate antigens on leukemic progenitors. RESULTS: A large number of potential targets for T-cell therapy or vaccination have now been identified in humanleukemia. Studies to evaluate novel immune-based therapies are now being initiated. CONCLUSIONS: The rapid pace of progress in cellular and molecular immunology has identified new opportunities for developing T-cell therapy or vaccination for leukemia. Obstacles must be addressed before these approaches can be applied broadly, but the promising results of preclinical studies suggest continued efforts in this area will result in the establishment of immunotherapy as a useful modality in clinical practice.
Authors: Ronald E Gress; Krishna V Komanduri; Hermann Einsele; Laurence J N Cooper Journal: Biol Blood Marrow Transplant Date: 2007-01 Impact factor: 5.742
Authors: Purnima Dubey; Helen Su; Nona Adonai; Shouying Du; Antonio Rosato; Jonathan Braun; Sanjiv S Gambhir; Owen N Witte Journal: Proc Natl Acad Sci U S A Date: 2003-01-23 Impact factor: 11.205